News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

KeystoneHeart Release:New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR



5/23/2013 6:52:37 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PARIS and CAESAREA, Israel, May 22, 2013 /PRNewswire/ --

•New clinical data presented from the DEFLECT-I study demonstrates that Keystone Heart's TriGuard™ Cerebral Protection Device reduces brain lesion volume during TAVR (Transcatheter Aortic Valve Replacement) procedures when compared to historical data.

Help employers find you! Check out all the jobs and post your resume.

Read at PR Newswire


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES